Ciprofloxacin in Current Clinical Practice | CMAC

Ciprofloxacin in Current Clinical Practice

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):154-162

​ Kozlov R.S., Golub A.V.
fluoroquinolones ciprofloxacin resistance efficacy
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):154-162

Abstract

Ciprofloxacin is the most known member of second generation quinolones, which is more active against gram-negative microorganisms and has broad antimicrobial spectrum compared to first generation quinolones. This article presents the main indications for usage of ciprofloxacin and data on resistance of significant pathogens to this fluoroquinolone. The data on clinical and microbiological efficacy of ciprofloxacin as a monotherapy or part of combination antimicrobial regimens, including data from comparative trials, in urinary tract infections (UTI), bacterial prostatitis, enteric infections and intra-abdominal infections (IAI) are considered. Potential for the use of ciprofloxacin in the treatment pelvic inflammatory diseases, skin and soft tissue infections (SSTI), bone and joint infections are also discussed. A focus on the role of ciprofloxacin in the treatment of hospital-acquired lower respiratory tract infections (nosocomial pneumonia) and acute exacerbation of COPD is made.

  • 1. Hooper D.C., Rubinstein E., editors. Quinolone antimicrobial agents. 3rd ed. Washington DC: ASM Press; 2003.
  • 2. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск: МАКМАХ; 2007. С. 94-100.
  • 3. Schito G., Naber K.G., Botto I., et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34:407-13.
  • 4. Лопаткин Н.А., Деревянко И.И., Страчунский Л.С., и др. Антибактериальная терапия неосложненного острого цистита и пиелонефрита у взрослых. Современные клинические рекомендации по антимикробной терапии. Выпуск 1. Смоленск: МАКМАХ; 2002. с. 156-68.
  • 5. Gilbert D.N. Urinary tract infections in patients with chronic renal insufficiency. Clinical Journal of the American Society of Nephrology 2006; 1:327-31.
  • 6. Gasser T.C., Ebert S.C., Graversen P.H., et al. Ciprofloxacin pharmacokinetics in patient with normal and impaired renal function. Antimicrob Agents Chemother 1987; 31:709-12.
  • 7. Elzinga L.W., Golper T.A., Rashad A.L., et al. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother 1988; 32:844-7.
  • 8. Hooton T.M., Scholes D., Gupta K., et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. JAMA 2005; 293:949-55.
  • 9. Talan D.A., Stamm W.E., Hooton T.M., et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in woman. JAMA 2000; 283:1583-90.
  • 10. Naber K.G., Bishop M.C., Bjerklund-Johansen T.E., et al. Рекомендации европейской урологической ассоциации по ведению больных с инфекциями почек, мочевыводящих путей и инфекциями мужских половых органов. Современные клинические рекомендации по антимикробной терапии. Выпуск 2. Смоленск: МАКМАХ; 2007. с. 352-565.
  • 11. Сухорукова М.В. Этиологическое значение различных микроорганизмов при хронических простатитах. [aвтореф. дис. … канд. мед. наук]. Смоленск, 2006. 21 с.
  • 12. Naber K.G., Weidner W. Chronic prostatitis – an infectious disease? JAC 2000; 46:157-61.
  • 13. Лобзин Ю.В., Якушин С.Б., Захаренко С.М. Практические рекомендации по ведению пациентов с инфекционной диареей. Современные клинические рекомендации по антимикробной терапии. Выпуск 1. Смоленск: МАКМАХ; 2002. с. 233-67.
  • 14. Guerrant R.L., Gilder T., Steiner T.S., et al. Practice guidelines for the management of infectious diarrhea. CID 2001; 32:331-51.
  • 15. Ahamed J., Gangopadhyay J., Kundu M., et al. Mechanisms of quinolone resistance in clinical isolates of Shigella dysenteriae. Antimicrob Agents Chemother 1999; 43:2333-4.
  • 16. Piddock L.J.V. Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 2002; 26:3-16.
  • 17. Bennish M.L., Salam M.A., Haider R., et al. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162:711-6.
  • 18. Khan W.A., Seas C., Dhar U., et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697-703.
  • 19. Ericsson C.D., Johnson P.C., DuPont H.L., et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers` diarrhea. A placebo-controlled, randomized trial. Ann Intern Med 1987; 106:216-20.
  • 20. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surgical Infections 2002; 3:161-73.
  • 21. Carlet J., Bouhaja B., Blériot J., Dazza F. Infections péritonéales postopératoires. In: L’infection en réani­mation. Régnier B., Brun-Buisson C., éds. Masson, Paris, 1988; 126-38.
  • 22. Зузова А.П., Стецюк О.У., Середкина М.А., и др. Этиология осложненных интраабдоминальных инфекций. Clinical Microbiology and Antimicrobial Chemotherapy.2001; 3 (Приложение 1):16.
  • 23. Walker A.P., Krepel C.J., Gohr C.M., et al. Microflora of abdominal sepsis: locus of infection. J Clin Microbiol 1994; 32:557-8.
  • 24. Solomkin J.S., Mazuski J.E., Baron E.J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997- 1005.
  • 25. Hospital-acquired pneumonia guideline committee of the American Thoracic Society & Infection Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
  • 26. Kollef M.H. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396-405.
  • 27. Craven D.E., Palladino R., McQuillen D.P. Healthcareassociated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am 2004; 18:939-62.
  • 28. Чучалин А.Г., Синопальников А.И., Страчунский Л. С., Козлов Р.С. и др. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. Современные клинические рекомендации по антимикробной терапии. Выпуск 2. Смоленск: МАКМАХ; 2007. с. 305-51.
  • 29. Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54:1408-13.
  • 30. Mapel D., Chen J.C., George D., et al. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag Care Interface 2004; 17:61-6.
  • 31. Anzueto A., Niederman M.S., Tillotson G.D., et al. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg BID vs clarithromycin 500 mg BID. Clin Ther 1998; 20:885-900.
  • 32. Chodosh S., Schreurs J.M., Siami G., et al. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27:730-8.
  • 33. Read R.C., Kuss A., Berrisoul F., et al. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbation of chronic bronchitis. Respir Med 1999; 93:252-61.
  • 34. Синопальников А.И., Козлов Р.С. Внебольничные инфекции дыхательных путей. Руководство для врачей. М.: Премьер МТ, Наш Город, 2007. c. 267-94.
  • 35. File T.M., Stevens D.L. Contemporary diagnosis and management of skin and soft-tissue infections. 2nd ed. Newtown: Handbooks in Health Care Co.; 2007.
  • 36. West M.A. Contemporary guide to surgical infections. Newtown: Handbooks in Health Care Co.; 2008.
  • 37. Moreno F., Crisp C., Jorgenson J.H., et al. Methicillinresistant Staphylococcus aureus as a community organism. Clin Infect 1995; 21:1308-12.
  • 38. Белькова Ю.А. Пиодермии в амбулаторной практике. Clinical Microbiology and Antimicrobial Chemotherapy.2005; 7:255- 70.
  • 39. Козлов Р.С., Сивая О.В., Шпынев К.В. и соавт. Анти­биотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клин. микробиол. антимикроб. химиотер. 2005; 7:154-66.
  • 40. Nikulin A., Dekhnich A., Ivanchik N., et al. Susceptibility of Staphylococcus aureus in the community settings in Russia. Proceedings of the 19th ECCMID; 2009 May 16-19; Helsinki, Finland. Poster# P1077.
  • 41. Haggerty C.L., Ness R.B. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. CID 2007; 44:953-60.
  • 42. CDC. Sexually transmitted disease surveillance 2005 supplement: Gonococcal Isolate Surveillance Project (GISP) annual report, 2005. Atlanta, GA: US Department of Health and Human Services, CDC; 2007. Available from: ULR: http://www.cdc.gov/std/GISP2005/default.htm.
  • 43. Heystek M., Tellarini M., Schmitz H., et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A):143.
  • 44. Arredondo J.L., Diaz V., Gaitan H., et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24:170-8.
  • 45. Ball P. Safety of the new fluoroquinolones compared with ciprofloxacin. Journal of chemotherapy 2000; 12 (Suppl. 1):8-11.
  • 46. Childs S.J. Safety of the fluoroquinolone antibiotics: focus on molecular structure. Infect Urol 2000; 13:3-10.
  • 47. Голуб А.В. Особенности фармацевтического рынка в XXI веке: единство непохожих и что мы выбираем? Clinical Microbiology and Antimicrobial Chemotherapy.2009; 11:335-40.
  • 48. Fourcroy J.L., Berner B., Chiang Y.K., et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005; 49:4137-43.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared